Immune Therapy Trial

The Sarcoidosis Program is offering a Phase II clinical trial to investigate the efficacy of immunological therapy in patients with chronic pulmonary sarcoidosis. As an NIH Center of Excellence for research in sarcoidosis, Mount Sinai is only one of two institutions in the country to offer the trial to patients.

"The current standard treatment for pulmonary sarcoidosis is corticosteroids. Many patients don’t respond to these drugs and those who do often develop long-term complications," said Adam Morgenthau , MD, principal investigator of the study and Director of the Sarcoidosis Clinic. "We are hopeful that this study will lead to new treatments to improve lung function and quality of life among patients with chronic sarcoidosis."

The 20-week clinical trial is designed to assess the safety and tolerability of an antibody directed against macrophage colony-stimulating factor (m-CSF), a protein associated with the development of sarcoidosis. The antibody was well tolerated in healthy volunteers and patients with rheumatoid arthritis during the Phase I trial.

The study is currently enrolling approximately ten patients and will continue to enroll up to 90. Patients in the study will receive infusion therapy every two weeks for 12 weeks, receive CT and PET scans and submit questionnaires during the study.

Eligibility

To participate in the study, patients must have chronic pulmonary sarcoidosis and lung impairment. Patients must also take corticosteroids daily.

For more information, visit our clinical trials page or contact Arika Manapat, study coordinator, at 212-241-9538.